Search research articles
Contact Us
Filters
Showing results (81-90 of 148) with videos related to
Page
of 15
Sort By:
British Journal of Cancer
|
January 29, 2024
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
Howard A Burris, Jordan Berlin, Tobias Arkenau, et al.
The New England Journal of Medicine
|
June 4, 2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, et al.
International Journal of Cancer
|
April 11, 2024
Circulating microRNAs in association with pancreatic cancer risk within 5 years
Cong Wang, Hui Cai, Qiuyin Cai, et al.
JAMA Network Open
|
October 27, 2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Satya Das, Liping Du, Cody L Lee, et al.
Investigational New Drugs
|
July 25, 2019
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
S Lindsey Davis, Dana B Cardin, Safi Shahda, et al.
Archives of Pathology & Laboratory Medicine
|
October 2, 2009
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum
Mary Kay Washington, Jordan Berlin, Philip Branton, et al.
Investigational New Drugs
|
February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
Saiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs
|
February 28, 2022
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
Saiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs
|
June 4, 2014
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
Kristen K Ciombor, Yang Feng, Al Bowen Benson, et al.
Investigational New Drugs
|
February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Jordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 148) with videos related to
Sort By:
Page
of 15
British Journal of Cancer
|
January 29, 2024
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
Howard A Burris, Jordan Berlin, Tobias Arkenau, et al.
The New England Journal of Medicine
|
June 4, 2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, et al.
International Journal of Cancer
|
April 11, 2024
Circulating microRNAs in association with pancreatic cancer risk within 5 years
Cong Wang, Hui Cai, Qiuyin Cai, et al.
JAMA Network Open
|
October 27, 2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Satya Das, Liping Du, Cody L Lee, et al.
Investigational New Drugs
|
July 25, 2019
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
S Lindsey Davis, Dana B Cardin, Safi Shahda, et al.
Archives of Pathology & Laboratory Medicine
|
October 2, 2009
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum
Mary Kay Washington, Jordan Berlin, Philip Branton, et al.
Investigational New Drugs
|
February 12, 2022
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
Saiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs
|
February 28, 2022
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
Saiama N Waqar, Clifford Robinson, Anthony J Olszanski, et al.
Investigational New Drugs
|
June 4, 2014
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
Kristen K Ciombor, Yang Feng, Al Bowen Benson, et al.
Investigational New Drugs
|
February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Jordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Page
of 15